Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766529 | 0.86 | EPHX2 (0.41) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL20766503 | 0.83 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20766457 | 0.83 | EPHX2 (0.62) | SLC6A4SLC6A2EPHX2 | |
| SCHEMBL950739 | 0.82 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL950740 | 0.82 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL20766484 | 0.81 | OPRL1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20766245 | 0.81 | HPGD (0.43) | SLC6A4SLC6A2 | |
| SCHEMBL20766492 | 0.81 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1780813 | 0.76 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31532355 | 0.75 | P2RX7 (0.46) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |